Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
Business Wire (Tue, 21-Apr 8:00 AM ET)
Cathie Wood's Ark Invest buys proteomics company Alamar, Netflix; trims crypto names
Seeking Alpha News (Mon, 20-Apr 6:59 AM ET)
Twist Bioscience to Present at Upcoming Investor Conferences
Business Wire (Wed, 18-Feb 8:00 AM ET)
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
Business Wire (Tue, 17-Feb 7:00 AM ET)
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
Business Wire (Tue, 10-Feb 8:00 AM ET)
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Tue, 3-Feb 8:00 AM ET)
Twist Bioscience Delivers Fiscal Q1 2026 Results—Innovative Platform Drives Growth Focus
Market Chameleon (Mon, 2-Feb 2:52 AM ET)
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results
Business Wire (Mon, 2-Feb 7:15 AM ET)
Twist Bioscience Highlights Robust Growth and Innovation in Fiscal 2025 Results
Market Chameleon (Fri, 14-Nov 3:18 AM ET)
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Twist Bioscience trades on the NASDAQ stock market under the symbol TWST.
As of April 21, 2026, TWST stock price climbed to $63.79 with 592,058 million shares trading.
TWST has a beta of 1.37, meaning it tends to be more sensitive to market movements. TWST has a correlation of 0.08 to the broad based SPY ETF.
TWST has a market cap of $3.90 billion. This is considered a Mid Cap stock.
Last quarter Twist Bioscience reported $104 million in Revenue and -$.50 earnings per share. This beat revenue expectation by $974,498 and met earnings estimates .
In the last 3 years, TWST traded as high as $65.10 and as low as $11.46.
The top ETF exchange traded funds that TWST belongs to (by Net Assets): ARKK, XBI, ARKG, VTI, IWM.
TWST has outperformed the market in the last year with a price return of +73.3% while the SPY ETF gained +35.7%. TWST has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +53.2% and +24.6%, respectively, while the SPY returned +4.6% and +7.3%, respectively.
TWST support price is $58.69 and resistance is $65.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TWST shares will trade within this expected range on the day.